MX2016010171A - Metodos para producir celulas t autologas utiles para tratar desordenes de celulas b y otros tipos de cancer, y composiciones de las mismas. - Google Patents
Metodos para producir celulas t autologas utiles para tratar desordenes de celulas b y otros tipos de cancer, y composiciones de las mismas.Info
- Publication number
- MX2016010171A MX2016010171A MX2016010171A MX2016010171A MX2016010171A MX 2016010171 A MX2016010171 A MX 2016010171A MX 2016010171 A MX2016010171 A MX 2016010171A MX 2016010171 A MX2016010171 A MX 2016010171A MX 2016010171 A MX2016010171 A MX 2016010171A
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- population
- methods
- serum
- culture medium
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 10
- 238000000034 method Methods 0.000 title abstract 5
- 210000004027 cell Anatomy 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 2
- 230000036210 malignancy Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000004017 serum-free culture medium Substances 0.000 abstract 3
- 108010001857 Cell Surface Receptors Proteins 0.000 abstract 2
- 210000004698 lymphocyte Anatomy 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 102000006240 membrane receptors Human genes 0.000 abstract 2
- 230000026683 transduction Effects 0.000 abstract 2
- 238000010361 transduction Methods 0.000 abstract 2
- 239000002269 analeptic agent Substances 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 230000002463 transducing effect Effects 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
En la presente se proporcionan métodos para la fabricación de células T; en ciertas modalidades se proporcionan métodos para fabricar células T que expresan un receptor de superficie celular que reconoce una porción antigénica específica en la superficie de una célula objetivo; dichos métodos pueden incluir, pero no se limitan a, los pasos de (1) enriquecer una población de linfocitos obtenidos de un sujeto donador; (2) estimular la población de linfocitos con uno o más agentes estimuladores de la célula T para producir una población de células T activadas, en donde la estimulación se realiza en un sistema cerrado utilizando un medio de cultivo libre de suero; (3) transducir la población de células T activadas con un vector viral que comprende una molécula de ácido nucleico que codifica para el receptor de superficie celular, usando una transducción de ciclo sencillo para producir una población de células T transducidas, en donde la transducción se realiza en un sistema cerrado utilizando un medio de cultivo libre de suero; y (4) expandir la población de células T transducidas durante un tiempo predeterminado para producir una población de células T diseñadas, en donde la expansión se realiza en un sistema cerrado utilizando un medio de cultivo libre de suero; también se proporcionan en la presente poblaciones de células T diseñadas producidas por los métodos que describen en la presente y sus composiciones farmacéuticas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461935833P | 2014-02-04 | 2014-02-04 | |
| PCT/US2015/014520 WO2015120096A2 (en) | 2014-02-04 | 2015-02-04 | Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016010171A true MX2016010171A (es) | 2017-02-15 |
Family
ID=53778605
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016010171A MX2016010171A (es) | 2014-02-04 | 2015-02-04 | Metodos para producir celulas t autologas utiles para tratar desordenes de celulas b y otros tipos de cancer, y composiciones de las mismas. |
| MX2023010870A MX2023010870A (es) | 2014-02-04 | 2023-09-14 | Métodos para producir células t autólogas útiles para tratar enfermedades malignas de las células b y otros cánceres y sus composiciones |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023010870A MX2023010870A (es) | 2014-02-04 | 2023-09-14 | Métodos para producir células t autólogas útiles para tratar enfermedades malignas de las células b y otros cánceres y sus composiciones |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US20150344844A1 (es) |
| EP (3) | EP4215603A1 (es) |
| JP (4) | JP2017505819A (es) |
| KR (5) | KR20200032763A (es) |
| CN (4) | CN114395530A (es) |
| AU (4) | AU2015214145A1 (es) |
| CA (1) | CA2937938A1 (es) |
| DK (1) | DK3102609T3 (es) |
| ES (1) | ES2989838T3 (es) |
| FI (2) | FI3102609T3 (es) |
| FR (1) | FR25C1009I1 (es) |
| HR (1) | HRP20241270T1 (es) |
| HU (2) | HUE069092T2 (es) |
| IL (4) | IL290744B2 (es) |
| LT (2) | LT3102609T (es) |
| MX (2) | MX2016010171A (es) |
| NO (1) | NO2025012I1 (es) |
| PL (1) | PL3102609T3 (es) |
| PT (1) | PT3102609T (es) |
| RS (1) | RS66199B1 (es) |
| SI (1) | SI3102609T1 (es) |
| SM (1) | SMT202400465T1 (es) |
| WO (1) | WO2015120096A2 (es) |
Families Citing this family (164)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013035101A1 (en) | 2011-09-11 | 2013-03-14 | Minovia Therapeutics Ltd. | Compositions of functional mitochondria and uses thereof |
| EP3333186B9 (en) | 2012-03-28 | 2023-10-04 | Gadeta B.V. | Combinatorial gamma 9 delta 2 t cell receptor chain exchange |
| ES2800906T3 (es) | 2014-04-25 | 2021-01-05 | Bluebird Bio Inc | Métodos mejorados para producir terapias celulares adoptivas |
| RU2719030C2 (ru) * | 2014-06-06 | 2020-04-16 | Блубёрд Био, Инк. | Улучшенные композиции на основе t-клеток |
| RU2747457C2 (ru) | 2014-07-24 | 2021-05-05 | Блубёрд Био, Инк. | Химерные антигенные рецепторы к bcma |
| EA036379B1 (ru) | 2014-12-12 | 2020-11-02 | Блубёрд Био, Инк. | Химерные антигенные рецепторы к bcma |
| JP2018510627A (ja) * | 2015-03-10 | 2018-04-19 | レイデン ユニバーシティ メディカル センター | メラノーマ優先発現抗原に対して向けられたｔ細胞レセプターおよびその使用 |
| EA202090931A3 (ru) | 2015-05-18 | 2020-10-30 | Тср2 Терапьютикс Инк. | Композиции и способы перепрограммирования tcr с помощью гибридных белков |
| HK1253335A1 (zh) | 2015-06-01 | 2019-06-14 | Sarepta Therapeutics, Inc. | 在vii型胶原蛋白中反义诱导外显子的排除 |
| WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
| WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
| WO2017099712A1 (en) | 2015-12-07 | 2017-06-15 | Bluebird Bio, Inc. | Improved t cell compositions |
| SI3436030T1 (sl) | 2016-04-01 | 2023-01-31 | Kite Pharma, Inc. | Himerni receptorji in načini njihove uporabe |
| IL261941B2 (en) | 2016-04-01 | 2023-11-01 | Kite Pharma Inc | Chimeric antigen and T cell receptors and methods of use |
| TWI761831B (zh) | 2016-04-01 | 2022-04-21 | 美商凱特製藥公司 | 嵌合抗原受體（ｃａｒ）和ｔ細胞受體（ｔｃｒ）及彼等之用途 |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| KR102489954B1 (ko) | 2016-06-10 | 2023-01-19 | 가데타 비.브이. | 인간 백혈구 항원 제한된 감마 델타 t 세포 수용체 및 이의 사용 방법 |
| EP3491152B1 (en) * | 2016-07-29 | 2022-06-29 | Juno Therapeutics, Inc. | Methods for assessing the presence or absence of replication competent virus |
| JP7109789B2 (ja) | 2016-08-02 | 2022-08-01 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法 |
| US20190262399A1 (en) | 2016-09-07 | 2019-08-29 | The Broad Institute, Inc. | Compositions and methods for evaluating and modulating immune responses |
| CN112280796A (zh) | 2016-10-07 | 2021-01-29 | T细胞受体治疗公司 | 使用融合蛋白进行t细胞受体重编程的组合物和方法 |
| JP2020500031A (ja) * | 2016-10-11 | 2020-01-09 | ミネルバ バイオテクノロジーズ コーポレーション | ヒト化抗ｍｕｃ１＊抗体及び開裂酵素の使用 |
| CA3042424A1 (en) | 2016-11-04 | 2018-05-11 | Bluebird Bio, Inc. | Anti-bcma car t cell compositions |
| CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| CN110234756A (zh) * | 2017-01-18 | 2019-09-13 | F1肿瘤医学公司 | 转导和扩增免疫细胞的方法及其用途 |
| WO2018144535A1 (en) | 2017-01-31 | 2018-08-09 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
| TW201837175A (zh) | 2017-03-13 | 2018-10-16 | 美商凱特製藥公司 | 用於黑色素瘤之嵌合抗原受體及其用途 |
| US20200077644A1 (en) * | 2017-03-14 | 2020-03-12 | Juno Therapeutics, Inc. | Methods for cryogenic storage |
| WO2018183908A1 (en) | 2017-03-31 | 2018-10-04 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
| EP3606518A4 (en) | 2017-04-01 | 2021-04-07 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER |
| EP3610266A4 (en) | 2017-04-12 | 2021-04-21 | Massachusetts Eye and Ear Infirmary | TUMOR SIGNATURE OF METASTASIS, COMPOSITIONS OF SUBSTANCES AND USES THEREOF |
| WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| WO2018201051A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| EP3622092A4 (en) | 2017-05-11 | 2021-06-23 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| AU2018367896B2 (en) | 2017-05-12 | 2023-06-01 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| CA3063807A1 (en) | 2017-05-18 | 2018-11-22 | Umc Utrecht Holding B.V. | Compositions and methods for cell targeting therapies |
| CN110740734A (zh) | 2017-06-07 | 2020-01-31 | 西雅图基因公司 | 具有降低的表面岩藻糖基化的t细胞及其制备和使用方法 |
| US11897953B2 (en) | 2017-06-14 | 2024-02-13 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
| WO2019011879A1 (en) | 2017-07-09 | 2019-01-17 | Rainer Henning | THERAPEUTIC AGENT FOR THE TREATMENT OF CAPILLARY LEAK SYNDROME |
| US12049643B2 (en) | 2017-07-14 | 2024-07-30 | The Broad Institute, Inc. | Methods and compositions for modulating cytotoxic lymphocyte activity |
| CN109423525A (zh) * | 2017-08-24 | 2019-03-05 | 上海恒润达生生物科技有限公司 | 一种表达car的逆转录病毒放行检测方法 |
| CN109420168A (zh) * | 2017-08-31 | 2019-03-05 | 海南诺倍尔生态医学科学研究院有限公司 | 一种抑制wt1基因突变的生物制剂制备技术 |
| CN114958772A (zh) | 2017-09-01 | 2022-08-30 | 隆萨沃克斯维尔股份有限公司 | 端到端细胞治疗自动化 |
| US12043870B2 (en) | 2017-10-02 | 2024-07-23 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
| WO2019079569A1 (en) | 2017-10-18 | 2019-04-25 | Novartis Ag | COMPOSITIONS AND METHODS FOR SELECTIVE DEGRADATION OF A PROTEIN |
| AU2018351046A1 (en) * | 2017-10-18 | 2020-04-30 | Kite Pharma, Inc. | Methods of administering chimeric antigen receptor immunotherapy |
| US11732257B2 (en) | 2017-10-23 | 2023-08-22 | Massachusetts Institute Of Technology | Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries |
| CN118256563A (zh) * | 2017-11-10 | 2024-06-28 | 北京卡替医疗技术有限公司 | 一种扩增免疫细胞的方法 |
| EP3710039A4 (en) | 2017-11-13 | 2021-08-04 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH |
| WO2019094955A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas |
| CA3088095A1 (en) | 2017-11-15 | 2019-05-23 | Novartis Ag | Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies |
| TW201925782A (zh) | 2017-11-30 | 2019-07-01 | 瑞士商諾華公司 | 靶向bcma之嵌合抗原受體及其用途 |
| US11994512B2 (en) | 2018-01-04 | 2024-05-28 | Massachusetts Institute Of Technology | Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity |
| CN112218651A (zh) | 2018-01-08 | 2021-01-12 | 诺华公司 | 用于与嵌合抗原受体疗法组合的免疫增强rna |
| US20210023134A1 (en) | 2018-01-15 | 2021-01-28 | Pfizer Inc. | Methods of administering chimeric antigen receptor immunotherapy in combination with 4-1bb agonist |
| AU2019215031B2 (en) | 2018-01-31 | 2025-10-09 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
| US10889792B2 (en) | 2018-02-09 | 2021-01-12 | Global Life Sciences Solutions Usa Llc | Cell expansion vessel systems and methods |
| SG11202007140XA (en) * | 2018-02-09 | 2020-08-28 | Global Life Sciences Solutions Usa Llc | Bioprocessing methods for cell therapy |
| AU2019218093A1 (en) * | 2018-02-09 | 2020-09-10 | Immatics US, Inc. | Methods for manufacturing T cells |
| WO2019160956A1 (en) | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| US11149244B2 (en) | 2018-04-04 | 2021-10-19 | Southwest Research Institute | Three-dimensional bioreactor for T-cell activation and expansion for immunotherapy |
| EA202092417A1 (ru) | 2018-04-10 | 2021-01-26 | Амген Инк. | Химерные рецепторы к dll3 и способы их применения |
| CN108575986A (zh) * | 2018-04-25 | 2018-09-28 | 广州莱德尔生物科技有限公司 | 一种保存液组合物及其应用 |
| US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
| MX2020012028A (es) | 2018-05-11 | 2021-03-29 | Crispr Therapeutics Ag | Metodos y composiciones para tratar el cancer. |
| US20210371932A1 (en) | 2018-06-01 | 2021-12-02 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
| US20200003758A1 (en) | 2018-06-01 | 2020-01-02 | Kite Pharma, Inc. | Chimeric antigen receptor t cell therapy |
| US12036240B2 (en) | 2018-06-14 | 2024-07-16 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
| US12239672B2 (en) | 2018-07-22 | 2025-03-04 | Minovia Therapeutics Ltd. | Mitochondrial augmentation therapy of ocular diseases |
| EP3823645B1 (en) | 2018-07-22 | 2024-07-03 | Minovia Therapeutics Ltd. | Mitochondrial augmentation therapy of renal diseases |
| WO2020021539A1 (en) | 2018-07-22 | 2020-01-30 | Minovia Therapeutics Ltd. | Mitochondrial augmentation therapy of muscle diseases |
| EP3823646A4 (en) | 2018-07-22 | 2022-06-08 | Minovia Therapeutics Ltd. | Mitochondrial augmentation therapy of brain diseases |
| KR20210035212A (ko) | 2018-07-22 | 2021-03-31 | 미노비아 테라퓨틱스 리미티드 | 원발성 미토콘드리아 질환을 위한 미토콘드리아 확대 요법 |
| AU2019311077B2 (en) * | 2018-07-23 | 2025-05-29 | Heidelberg Pharma Research Gmbh | Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy |
| CA3107378A1 (en) * | 2018-07-23 | 2020-01-30 | Magenta Therapeutics, Inc. | Use of an anti-cd2 antibody drug conjugate (adc) in allogeneic cell therapy |
| SG11202101014XA (en) * | 2018-08-02 | 2021-02-25 | Kite Pharma Inc | Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof |
| EP3844265A2 (en) | 2018-08-31 | 2021-07-07 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
| SG11202101825QA (en) | 2018-08-31 | 2021-03-30 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| JP7376576B2 (ja) | 2018-09-24 | 2023-11-08 | サウスウェスト リサーチ インスティテュート | 三次元バイオリアクター |
| JP7396777B2 (ja) | 2018-09-28 | 2023-12-12 | オクタン バイオテック インコーポレーテッド | 磁気分離 |
| US20210382068A1 (en) | 2018-10-02 | 2021-12-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
| WO2020081730A2 (en) | 2018-10-16 | 2020-04-23 | Massachusetts Institute Of Technology | Methods and compositions for modulating microenvironment |
| WO2020088631A1 (en) | 2018-11-01 | 2020-05-07 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for t cell engineering |
| WO2020114491A1 (en) * | 2018-12-07 | 2020-06-11 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for immunotherapy |
| WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
| IL284214B2 (en) | 2018-12-21 | 2025-03-01 | Octane Biotech Inc | Carousel for modular biologic production units |
| JP7598864B2 (ja) | 2018-12-21 | 2024-12-12 | ロンザ ウォーカーズヴィル，インコーポレーテッド | ウイルスベクターの自動産生方法 |
| US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
| CN113498432A (zh) | 2019-02-08 | 2021-10-12 | 隆萨沃克斯维尔股份有限公司 | 用于自动化生物反应器的细胞浓缩方法和装置 |
| EP3927847A4 (en) | 2019-02-22 | 2023-04-19 | Garvan Institute of Medical Research | METHODS OF MODULATING THE IMMUNE RESPONSE THROUGH A20 SNVS THAT CAN "CALIBRATE" THE IMMUNE SYSTEM OF A SUBJECT |
| BR112021016609A2 (pt) | 2019-02-25 | 2021-11-03 | Novartis Ag | Composições de partículas de sílica mesoporosa para entrega viral |
| PH12021551720A1 (en) | 2019-03-01 | 2022-03-28 | Allogene Therapeutics Inc | Dll3 targeting chimeric antigen receptors and binding agents |
| SG11202109057XA (en) | 2019-03-05 | 2021-09-29 | Nkarta Inc | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| US20220154282A1 (en) | 2019-03-12 | 2022-05-19 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
| US20220142948A1 (en) | 2019-03-18 | 2022-05-12 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
| US20230074800A1 (en) | 2019-03-21 | 2023-03-09 | Novartis Ag | Car-t cell therapies with enhanced efficacy |
| JP7638881B2 (ja) | 2019-03-21 | 2025-03-04 | アロジーン セラピューティクス，インコーポレイテッド | ＴＣＲαβ＋細胞の枯渇効率を向上させる方法 |
| WO2020210678A1 (en) | 2019-04-12 | 2020-10-15 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| US20220251152A1 (en) | 2019-04-24 | 2022-08-11 | Novartis Ag | Compositions and methods for selective protein degradation |
| ES2961314T3 (es) | 2019-04-26 | 2024-03-11 | Allogene Therapeutics Inc | Receptores quiméricos de antígeno resistentes a rituximab y usos de los mismos |
| EP3962535A1 (en) | 2019-04-30 | 2022-03-09 | CRISPR Therapeutics AG | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| CN118593691A (zh) | 2019-05-03 | 2024-09-06 | 凯德药业股份有限公司 | 施用嵌合抗原受体免疫疗法的方法 |
| US20220235340A1 (en) | 2019-05-20 | 2022-07-28 | The Broad Institute, Inc. | Novel crispr-cas systems and uses thereof |
| US20220226464A1 (en) | 2019-05-28 | 2022-07-21 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
| JP7606472B2 (ja) * | 2019-05-28 | 2024-12-25 | ミルテニイ ビオテック ベー．ファー． ウント コー．カーゲー | 遺伝子改変ｔ細胞の生成方法 |
| US20220282333A1 (en) | 2019-08-13 | 2022-09-08 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
| US12421557B2 (en) | 2019-08-16 | 2025-09-23 | The Broad Institute, Inc. | Methods for predicting outcomes and treating colorectal cancer using a cell atlas |
| US20220298501A1 (en) | 2019-08-30 | 2022-09-22 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
| US12297426B2 (en) | 2019-10-01 | 2025-05-13 | The Broad Institute, Inc. | DNA damage response signature guided rational design of CRISPR-based systems and therapies |
| US12394502B2 (en) | 2019-10-02 | 2025-08-19 | The General Hospital Corporation | Method for predicting HLA-binding peptides using protein structural features |
| US11981922B2 (en) | 2019-10-03 | 2024-05-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment |
| US12195725B2 (en) | 2019-10-03 | 2025-01-14 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity |
| US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
| US12247188B2 (en) | 2019-10-24 | 2025-03-11 | Octane Biotech Inc. | Cell culture chamber with improved cell-contacting surfaces |
| IL292665B1 (en) * | 2019-11-06 | 2025-10-01 | Kite Pharma Inc | Chimeric antigen receptor T cell therapy |
| CN114667341A (zh) | 2019-11-11 | 2022-06-24 | 隆萨沃克斯维尔股份有限公司 | 用于自动化细胞处理的质量控制方法 |
| AU2020393912B2 (en) | 2019-11-26 | 2025-11-20 | Novartis Ag | Chimeric antigen receptors binding BCMA and CD19 and uses thereof |
| JP2023506184A (ja) | 2019-12-11 | 2023-02-15 | エイ２・バイオセラピューティクス・インコーポレイテッド | Ｌｉｌｒｂ１ベースのキメラ抗原受容体 |
| WO2021123832A1 (en) | 2019-12-20 | 2021-06-24 | Instil Bio (Uk) Limited | Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof |
| US12180444B2 (en) | 2019-12-30 | 2024-12-31 | Saint-Gobain Performance Plastics Corporation | Containers and methods for cell transduction |
| US12165747B2 (en) | 2020-01-23 | 2024-12-10 | The Broad Institute, Inc. | Molecular spatial mapping of metastatic tumor microenvironment |
| US20230106973A1 (en) | 2020-02-17 | 2023-04-06 | Board Of Regents, The University Of Texas System | Methods for expansion of tumor infiltrating lymphocytes and use thereof |
| CA3173394A1 (en) | 2020-02-27 | 2021-09-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| US20230174933A1 (en) | 2020-02-27 | 2023-06-08 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| WO2021199040A1 (en) * | 2020-03-31 | 2021-10-07 | Minovia Therapeutics Ltd. | Mitochondria-enriched genetically engineered cells and uses thereof |
| EP4133057A4 (en) * | 2020-04-10 | 2025-04-16 | Southwest Research Institute | Three-dimensional bioreactor for viral vector production |
| US12378521B2 (en) | 2020-04-15 | 2025-08-05 | Amgen Inc. | Method for enhancing production of genetically engineered autologous T cells |
| MX2022012990A (es) * | 2020-04-15 | 2023-01-11 | Amgen Inc | Proceso para generar células t autólogas modificadas genéticamente. |
| US12241086B2 (en) | 2020-04-15 | 2025-03-04 | Amgen Inc. | Process for generating genetically engineered autologous T cells |
| IL298473A (en) | 2020-06-11 | 2023-01-01 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| US20220047677A1 (en) | 2020-08-14 | 2022-02-17 | Kite Pharma, Inc. | Immune cell function |
| LT4058474T (lt) | 2020-08-20 | 2024-08-26 | A2 Biotherapeutics, Inc. | Kompozicijos ir būdai, skirti gydyti egfr atžvilgiu teigiamas vėžio formas |
| EP4100028A4 (en) | 2020-08-20 | 2023-07-26 | A2 Biotherapeutics, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF MESOTHELIN-POSITIVE CARCINOMAS |
| JP7657292B2 (ja) | 2020-08-20 | 2025-04-04 | エー２ バイオセラピューティクス， インコーポレイテッド | Ｃｅａｃａｍ陽性がんを治療するための組成物及び方法 |
| TW202227124A (zh) | 2020-08-21 | 2022-07-16 | 瑞士商諾華公司 | 用於體內產生ｃａｒ表現細胞的組成物和方法 |
| EP4237854A1 (en) | 2020-10-28 | 2023-09-06 | Kite Pharma, Inc. | Flow cytometric method for characterization of t-cell impurities |
| MX2023008662A (es) | 2021-01-28 | 2023-08-01 | Allogene Therapeutics Inc | Metodos para transducir celulas inmunitarias. |
| TW202245811A (zh) | 2021-02-03 | 2022-12-01 | 美商異基因治療有限公司 | 用於ｃａｒ ｔ細胞藥物產品的調配物與製程 |
| CA3172530A1 (en) | 2021-02-25 | 2022-09-01 | Spencer PARK | Ror1 targeting chimeric antigen receptor |
| JP7690597B2 (ja) | 2021-03-11 | 2025-06-10 | カイト ファーマ インコーポレイテッド | 免疫細胞機能の改善 |
| WO2022215718A1 (ja) * | 2021-04-08 | 2022-10-13 | 武田薬品工業株式会社 | Ｔ細胞活性化方法 |
| TW202309294A (zh) | 2021-04-27 | 2023-03-01 | 瑞士商諾華公司 | 病毒載體生產系統 |
| WO2023007431A1 (en) | 2021-07-29 | 2023-02-02 | Takeda Pharmaceutical Company Limited | Engineered immune cell that specifically targets mesothelin and uses thereof |
| CN117858901A (zh) | 2021-08-20 | 2024-04-09 | 诺华股份有限公司 | 制备表达嵌合抗原受体的细胞的方法 |
| CN115025217B (zh) * | 2022-05-13 | 2023-05-05 | 广东齐美医药生物科技集团有限公司 | 干细胞裂解物联合活性多糖以及酪氨酸酶抑制剂在制备药物或化妆品中的用途 |
| CN119173624A (zh) * | 2022-05-27 | 2024-12-20 | 凯德药业股份有限公司 | 用于制备用于细胞疗法的工程化淋巴细胞的组合物和方法 |
| CN115039763A (zh) * | 2022-07-15 | 2022-09-13 | 北京大学第三医院（北京大学第三临床医学院） | 一种免疫细胞冻存液 |
| EP4577234A1 (en) | 2022-08-26 | 2025-07-02 | Kite Pharma, Inc. | Improving immune cell function |
| WO2024077256A1 (en) | 2022-10-07 | 2024-04-11 | The General Hospital Corporation | Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins |
| AU2023369684A1 (en) | 2022-10-26 | 2025-04-17 | Novartis Ag | Lentiviral formulations |
| EP4608416A1 (en) | 2022-10-28 | 2025-09-03 | Kite Pharma, Inc. | Expedited administration of engineered lymphocytes |
| EP4608417A1 (en) | 2022-10-28 | 2025-09-03 | Kite Pharma, Inc. | Improving efficacy and durable response of immunotherapy |
| WO2024124044A1 (en) | 2022-12-07 | 2024-06-13 | The Brigham And Women’S Hospital, Inc. | Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression |
| WO2025059533A1 (en) | 2023-09-13 | 2025-03-20 | The Broad Institute, Inc. | Crispr enzymes and systems |
| WO2025083196A1 (en) * | 2023-10-18 | 2025-04-24 | Tq Therapeutics Gmbh | A method of manufacturing a cellular therapy product and respective kits and devices |
| WO2025096517A1 (en) | 2023-11-01 | 2025-05-08 | Kite Pharma, Inc. | Factors for optimizing immunotherapy efficacy |
| WO2025097055A2 (en) | 2023-11-02 | 2025-05-08 | The Broad Institute, Inc. | Compositions and methods of use of t cells in immunotherapy |
| WO2025117544A1 (en) | 2023-11-29 | 2025-06-05 | The Broad Institute, Inc. | Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof |
| US20250297219A1 (en) | 2024-02-08 | 2025-09-25 | Kite Pharma, Inc. | Methods for generating engineered lymphocytes with enriched t memory stem cells |
| WO2025174963A1 (en) | 2024-02-16 | 2025-08-21 | Kite Pharma, Inc. | Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy |
| US20250375480A1 (en) | 2024-06-11 | 2025-12-11 | Kite Pharma, Inc. | Methods for Generating Engineered Lymphocytes |
| WO2026015457A1 (en) | 2024-07-08 | 2026-01-15 | Kite Pharma, Inc. | Systems and methods for applying mechanical force to living cells to generate a phenotypic response |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008042814A2 (en) * | 2006-09-29 | 2008-04-10 | California Institute Of Technology | Mart-1 t cell receptors |
| JP5485139B2 (ja) * | 2008-03-27 | 2014-05-07 | タカラバイオ株式会社 | 遺伝子導入細胞の製造方法 |
| WO2010080032A2 (en) * | 2009-01-09 | 2010-07-15 | Stichting Het Nederlands Kanker Instituut | Bead-assisted viral transduction |
| PT3459560T (pt) * | 2011-04-08 | 2021-05-24 | Us Health | Recetores de antigénio quimérico variante iii de recetor de fator de crescimento antiepidérmico e utilização dos mesmos para o tratamento de cancro |
| MX2014003176A (es) * | 2011-09-16 | 2015-08-05 | Univ Pennsylvania | Celulas t diseñadas mediante arn para el tratamiento de cancer. |
| EP2594632A1 (en) * | 2011-11-18 | 2013-05-22 | Miltenyi Biotec GmbH | Method and device for cell modification |
| ES2708584T3 (es) * | 2014-04-24 | 2019-04-10 | Miltenyi Biotec Gmbh | Método para la generación automatizada de células T modificadas genéticamente |
-
2015
- 2015-02-04 PL PL15746399.3T patent/PL3102609T3/pl unknown
- 2015-02-04 IL IL290744A patent/IL290744B2/en unknown
- 2015-02-04 KR KR1020207007771A patent/KR20200032763A/ko not_active Ceased
- 2015-02-04 CN CN202111599342.6A patent/CN114395530A/zh active Pending
- 2015-02-04 PT PT157463993T patent/PT3102609T/pt unknown
- 2015-02-04 US US14/614,400 patent/US20150344844A1/en not_active Abandoned
- 2015-02-04 CN CN202510648653.9A patent/CN120536374A/zh active Pending
- 2015-02-04 DK DK15746399.3T patent/DK3102609T3/da active
- 2015-02-04 KR KR1020227027811A patent/KR102729771B1/ko active Active
- 2015-02-04 CN CN202510648656.2A patent/CN120536375A/zh active Pending
- 2015-02-04 EP EP23155129.2A patent/EP4215603A1/en active Pending
- 2015-02-04 KR KR1020167024014A patent/KR20160113295A/ko not_active Ceased
- 2015-02-04 SM SM20240465T patent/SMT202400465T1/it unknown
- 2015-02-04 FI FIEP15746399.3T patent/FI3102609T3/fi active
- 2015-02-04 MX MX2016010171A patent/MX2016010171A/es unknown
- 2015-02-04 LT LTEPPCT/US2015/014520T patent/LT3102609T/lt unknown
- 2015-02-04 WO PCT/US2015/014520 patent/WO2015120096A2/en not_active Ceased
- 2015-02-04 EP EP15746399.3A patent/EP3102609B1/en active Active
- 2015-02-04 ES ES15746399T patent/ES2989838T3/es active Active
- 2015-02-04 JP JP2016567484A patent/JP2017505819A/ja active Pending
- 2015-02-04 EP EP17154769.8A patent/EP3208330A1/en not_active Withdrawn
- 2015-02-04 HR HRP20241270TT patent/HRP20241270T1/hr unknown
- 2015-02-04 SI SI201532039T patent/SI3102609T1/sl unknown
- 2015-02-04 KR KR1020247037315A patent/KR20240164967A/ko active Pending
- 2015-02-04 AU AU2015214145A patent/AU2015214145A1/en not_active Abandoned
- 2015-02-04 KR KR1020217004191A patent/KR20210020165A/ko not_active Ceased
- 2015-02-04 IL IL312867A patent/IL312867A/en unknown
- 2015-02-04 RS RS20241262A patent/RS66199B1/sr unknown
- 2015-02-04 CA CA2937938A patent/CA2937938A1/en active Pending
- 2015-02-04 HU HUE15746399A patent/HUE069092T2/hu unknown
- 2015-02-04 CN CN201580016764.2A patent/CN106459915A/zh active Pending
-
2016
- 2016-08-03 IL IL247095A patent/IL247095B/en unknown
-
2018
- 2018-06-18 US US16/011,292 patent/US20190032011A1/en not_active Abandoned
-
2020
- 2020-01-22 JP JP2020007980A patent/JP7087011B2/ja active Active
- 2020-02-21 AU AU2020201292A patent/AU2020201292B2/en active Active
-
2021
- 2021-04-14 IL IL282352A patent/IL282352B/en unknown
-
2022
- 2022-06-08 JP JP2022092616A patent/JP7532445B2/ja active Active
- 2022-08-31 AU AU2022224780A patent/AU2022224780B2/en active Active
-
2023
- 2023-09-14 MX MX2023010870A patent/MX2023010870A/es unknown
- 2023-12-21 US US18/393,414 patent/US20240158748A1/en active Pending
-
2024
- 2024-07-31 JP JP2024124165A patent/JP7779960B2/ja active Active
-
2025
- 2025-02-19 FR FR25C1009C patent/FR25C1009I1/fr active Active
- 2025-02-20 AU AU2025201205A patent/AU2025201205A1/en active Pending
- 2025-02-20 FI FIC20250010C patent/FIC20250010I1/fi unknown
- 2025-02-25 NO NO2025012C patent/NO2025012I1/no unknown
- 2025-02-26 LT LTPA2025510C patent/LTPA2025510I1/lt unknown
- 2025-02-27 HU HUS2500012C patent/HUS2500012I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016010171A (es) | Metodos para producir celulas t autologas utiles para tratar desordenes de celulas b y otros tipos de cancer, y composiciones de las mismas. | |
| MX2019004708A (es) | Celulas que presentan antigeno artificial manipulado por ingenieria para expansion linfocitica infiltrante de tumores. | |
| MX2019003683A (es) | Anticuerpos anti gen 3 de activación linfocítica (lag 3 ) y métodos para usarlos. | |
| CL2018002792A1 (es) | Receptores quiméricos de flt3 y métodos de uso de los mismos. | |
| MX2024009690A (es) | Anticuerpos anti-cd137 y metodos de uso de los mismos. | |
| CO2019007092A2 (es) | Receptores inmunes sintéticos y métodos de uso de los mismos | |
| MX2021001523A (es) | Procesos para generar células modificadas y composiciones de las mismas. | |
| MX2019006340A (es) | Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) y métodos de uso de los mismos. | |
| BR112018068746A2 (pt) | vesículas de membrana terapêutica | |
| CY1122612T1 (el) | Μεθοδος | |
| MY189819A (en) | Genetically modified cells and uses thereof | |
| CO2018004937A2 (es) | Células asesinas naturales y células ilc3 y usos de las mismas | |
| MX2017003625A (es) | Reactivos y metodos para identificar, enriquecer y/o expander celulas t especificas de antigeno. | |
| PE20160950A1 (es) | Biomarcadores de cancer y usos de los mismos | |
| CL2016003324A1 (es) | Construcciones de anticuerpos multiespecificos. | |
| UY36554A (es) | ARNi VARIANTE | |
| BR112021008738A2 (pt) | Processo para produzir células t geneticamente construídas | |
| EA201690529A1 (ru) | Способы модификации клетки-хозяина | |
| BR112017014031A2 (pt) | n-oligossacaril-transferase recombinante, mutante de n-oligossacaril-transferase recombinante, ácido nucleico, célula hospedeira, e, método para produção de um bioconjugado. | |
| BR112016028512A8 (pt) | método de cultivo de uma célula de mamífero e método de produção de uma proteína recombinante | |
| MX2021009967A (es) | Metodos para producir celulas t autologas utiles para tratar cancer y composiciones de las mismas. | |
| MX2019011138A (es) | Antagonistas del receptor de hidrocarburo de arilo y sus usos. | |
| EA201891459A1 (ru) | Новое поколение антигенспецифических tcr | |
| CY1123467T1 (el) | Θεραπευτικο εμβολιο για τη θεραπεια του παιδικου διαβητη τυπου 1, εφαρμογη του κυτταροδιαχωριστη κυτταρομετριας ροης και της μεθοδου πολλαπλασιασμου των κυτταρων treg για την παραγωγη θεραπευτικου εμβολιου για τη θεραπεια του διαβητη τυπου 1 | |
| BR112015021189A2 (pt) | métodos de banco de células de alta densidade |